Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by alleyesonmeon Mar 31, 2024 3:23pm
80 Views
Post# 35961820

RE:RE:Unsolicited takeover bid…

RE:RE:Unsolicited takeover bid…I don't care what anyone says, I see the value, MPL will be profitable this year, the average LP in Canada paid 38% to the government in 2022 from the top line....this will change when the feds table the budget, April 16th, US rescheduling announcement will happen, I'm guessing before or on April 20th, and the Brazilian announcement may be much bigger than anyone anticipated, YTD dronabinol (delta9thc isolate) up 1500%, is proof the years long pharma play is beginning to pay off big with large contracted API contracts to be announced much like in 2019 for bulk distillate, in addition to already signed and in the works contract manufacturing agreements...I won't sell my shares cheap.
<< Previous
Bullboard Posts
Next >>